SadBaby, a company that aims at helping SMA (Spinal Muscular Atrophy) affected babies, has vowed to assist patients with newly launched crowdfunding platform that will emphasize on collecting funds from investors and supporters and use them to fulfill the financial requirements of SMA-impacted patients globally.
SMA (spinal muscular atrophy) is one of the most common causes of death in babies. It is a genetic disease that gradually destroys motor neurons—nerve cells in the spinal cord and brainstem which control the indispensable skeletal muscle activity. Activities like breathing, walking, speaking, and gulping are impacted due to muscle weakness and atrophy.
Notably, the cost of treating SMA disease is huge, and it is very challenging for parents to raise funds. In addition, a protein booster drug called ‘Spinraza’, which is licensed by Biogen Inc., must be applied regularly to the patient throughout life.
Sources claim that the estimated cost of the drug is around $625,000 to $750,000 in the beginning and later $375,000 each year. SadBaby intends to donate monetarily to SMA patients and support them in fighting the disease with donations from its angel investors and community.
It raises funds at numerous levels, from the smallest to the largest, by providing gifts, t-shirts, or the product itself to recognize its supporters for their donations. Additionally, the Sadbaby token can be profitable apart from just being a useful means for donation. Token holders can earn extra money by instantly staking their tokens in their wallets without a need to store the token elsewhere.
Taxes are being accompany with each token transaction, and a portion of it is returned back to the holders, thus compensating them for entrusting their valuable asset to SadBaby.
Credible reports state that the SadBaby platform plans to launch an NFT marketplace to assist families in selling NFT products and obtaining financial assistance. The marketplace is touted to be launched by the end of this year.